Physician profile
Ciro Attardo
NPI 1922052166
$2,903.48
in general payments reported to CMS, 2019-2025
25 companies · $27.57 in 2025
The $27.57 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,342 · 2020: $1,013 · 2021: $521 · 2025: $27.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $27.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $27.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $481.56 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $436.39 | 2019-2021 | |
| Novo Nordisk INC | $289.90 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.58 | 2019-2021 | |
| Amarin Pharma, INC. | $187.90 | 2019-2021 | |
| Glaxosmithkline, LLC. | $181.32 | 2019-2020 | |
| Pfizer INC. | $165.26 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $119.74 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $109.77 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.75 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $76.62 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $76.05 | 2019 | |
| Abbvie INC. | $67.92 | 2021 | |
| Sanofi Pasteur INC. | $52.57 | 2019-2025 | |
| Amgen INC. | $48.93 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $47.00 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $45.98 | 2019-2021 | |
| Allergan, INC. | $38.24 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $23.76 | 2019 | |
| Genentech USA, INC. | $18.58 | 2019 | |
| Seqirus USA INC | $16.25 | 2019 | |
| Eisai INC. | $15.64 | 2021 | |
| Bardy Diagnostics, INC. | $15.00 | 2021 | |
| Currax Pharmaceuticals LLC | $11.46 | 2021 | |
| Abbott Laboratories | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ciro Attardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.